Payment overview · 2025
General Payments
$111.39
6 reported records · 4 companies
Healthcare provider profile · identity verified
Bryan D. Tate, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · KENTWOOD, LA · NPI 1407177348
Verified facts
What the public records show
CMS Open Payments records show Bryan D. Tate, FNP-C received $111.39 in general payments during 2025 across 6 reported records.
TOLMAR, INC. accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $48.14 | 43.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.51 | 22.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.89 | 19.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.85 | 15.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.39 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $48.14 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 321 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 58 |
| Losartan Potassium | Losartan Potassium | 303 | 55 |
| Meloxicam | Meloxicam | 296 | 63 |
| Metformin Hcl | Metformin Hcl | 249 | 44 |
| Lisinopril | Lisinopril | 235 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 37 |
| Furosemide | Furosemide | 211 | 51 |
| Gabapentin | Gabapentin | 206 | 52 |
| Potassium Chloride | Potassium Chloride | 182 | 35 |
| Carvedilol | Carvedilol | 176 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 39 |
| Glimepiride | Glimepiride | 171 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 32 |
| Mounjaro | Tirzepatide | 137 | 22 |
| Eliquis | Apixaban | 133 | 28 |
| Omeprazole | Omeprazole | 128 | 29 |
| Nifedipine Er | Nifedipine | 125 | 20 |
| Trazodone Hcl | Trazodone Hcl | 122 | 25 |
| Simvastatin | Simvastatin | 120 | 19 |
| Montelukast Sodium | Montelukast Sodium | 116 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 37 |
| Methylprednisolone | Methylprednisolone | 102 | 86 |
| Jardiance | Empagliflozin | 100 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 22 |
| Celecoxib | Celecoxib | 94 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 20 |
| Alprazolam | Alprazolam | 87 | 21 |
| Ozempic | Semaglutide | 83 | 18 |
| Ezetimibe | Ezetimibe | 81 | 18 |
| Clonazepam | Clonazepam | 79 | 14 |
| Allopurinol | Allopurinol | 75 | 17 |
| Bupropion Xl | Bupropion Hcl | 71 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 40 |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Spironolactone | Spironolactone | 69 | 15 |
| Buspirone Hcl | Buspirone Hcl | 66 | 17 |
| Famotidine | Famotidine | 66 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Azithromycin | Azithromycin | 58 | 49 |
| Sertraline Hcl | Sertraline Hcl | 58 | 12 |
| Temazepam | Temazepam | 58 | 15 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Methocarbamol | Methocarbamol | 55 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | suppressed |
| Glipizide | Glipizide | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 11 |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Valsartan | Valsartan | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 14 |
| Cephalexin | Cephalexin | 47 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 28 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 11 |
| Estradiol | Estradiol | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 13 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 14 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Linzess | Linaclotide | 33 | 12 |
| Atenolol | Atenolol | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Prednisone | Prednisone | 28 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | 11 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 23 |
| Anastrozole | Anastrozole | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 16 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | 13 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.39 · 6 records | TOLMAR, INC. | Auvelity, JATENZO, OTEZLA, Ozempic, REPATHA, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error